How ancestry and sex affect responses to blood-thinning medications
Official title: Ancestry and sex-related pharmacogenomic and metabolomic signatures of oral anticoagulant response
Funded at University of Alabama at Birmingham · NIH-10886294 · Data updated 2026-11-12
This study is looking at how your genes and gender might affect how well blood thinners like warfarin work for you, with the goal of making these medications safer and more effective for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | September 18, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $169,222 |
| NIH project number | 1K23HL165031-01A1 |
| Project ID | NIH-10886294 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are prescribed oral anticoagulants and belong to diverse ancestry groups, particularly African American women.
✕Less likely to help
Patients who are not taking oral anticoagulants or do not belong to the targeted ancestry groups may not benefit from this research.
What this research studies
This research investigates how genetic factors related to ancestry and sex influence the effectiveness and safety of oral anticoagulants (blood thinners) like warfarin and direct oral anticoagulants. By examining pharmacogenomic and metabolomic signatures, the study aims to understand why some individuals experience adverse effects or inadequate treatment outcomes. The research will involve analyzing genetic variations and metabolite profiles to personalize anticoagulant therapy, ultimately improving patient care. Participants may contribute to identifying new therapeutic targets and biomarkers that can enhance treatment strategies for diverse populations.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective anticoagulant therapies, reducing the risk of complications for patients.
How similar studies have gone: Previous research has shown promise in using pharmacogenomics to tailor anticoagulant therapy, but this study aims to expand on those findings by including diverse populations and sex-related factors.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Davis, Brittney H — University of Alabama at Birmingham
- Study coordinator: Davis, Brittney H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.